DelMar Pharmaceuticals (NASDAQ:DMPI) released its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01, Fidelity Earnings reports.
Shares of DelMar Pharmaceuticals stock opened at $0.82 on Tuesday. The firm has a market cap of $17.62 million, a price-to-earnings ratio of -1.11 and a beta of 1.78. DelMar Pharmaceuticals has a one year low of $0.33 and a one year high of $1.82.
Separately, ValuEngine upgraded shares of DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 2nd.
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
See Also: Should You Consider an Index Fund?
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.